NCT07329153尚未招募不适用
Neuronavigated and Non-Neuronavigated Accelerated Intermittent Theta-Burst Stimulation for Treatment-Resistant Depression A Sham-Controlled Randomized Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 247
- 试验地点
- 3
- 主要终点
- HDRS-17 - Depression severity assessment
研究概览
简要总结
The purpose of this study is to confirm the efficacy of two recently introduced repetitive transcranial magnetic stimulation (rTMS) interventions - accelerated intermittent theta-burst stimulation (aiTBS) and individualized neuronavigation - in treatment-resistant depression (TRD). Using a three-arm design (neuronavigated aiTBS, non-neuronavigated aiTBS, and sham), this randomized controlled trial (RCT) is the first to specifically investigate the incremental benefit of neuronavigation within an accelerated stimulation protocol, as well as the first confirmatory RCT comparing the efficacy of each of these active treatments vs. sham, overcoming previous generalizability issues and being conducted in an independent, multicenter US TRD sample.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18 to 65 years at the time of consent
- •Diagnosis: Current major depressive episode (MDE) in the context of unipolar major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by clinical psychiatric interview
- •Treatment Resistance: Documented failure to respond to at least two adequate antidepressant trials on the Antidepressant Treatment History Form-Short Form (ATHF-SF). An adequate trial is defined as:
- •Antidepressant medication at the maximum tolerated dose for at least 6 weeks, OR
- •Evidence-based psychotherapy consisting of at least 12 sessions
- •Depression Severity: Montgomery-Åsberg Depression Rating Scale (MADRS) score >19 at screening, indicating moderate to severe depression
- •Medication Stability: No changes in antidepressant medication type or dose for at least 6 weeks prior to randomization. Stable doses of permitted medications must be maintained throughout the trial
- •Informed Consent: Demonstrated capacity to provide written informed consent and comply with study procedures
- •Availability: Ability to attend treatment sessions for 15 consecutive workdays (approximately 90 minutes per day) and complete assessments including 4-hour evaluations at baseline and endpoint
排除标准
- •Psychiatric Exclusions:
- •Any psychiatric disorder other than MDD and comorbid anxiety disorders, including but not limited to:
- •(i) Bipolar disorder (Type I or II) (ii) Schizophrenia spectrum or other psychotic disorders (iii) Post-traumatic stress disorder (PTSD) (iv) Attention-deficit/hyperactivity disorder (ADHD) (v) Autism spectrum disorder (ASD) (vi) Obsessive-compulsive disorder (OCD) (vii) Current DSM-5 substance-use disorder (abuse or dependence) within the past 6 months, except nicotine dependence
- •Personality disorder confirmed on clinical interview by an experienced study psychiatrist
- •Severe suicidal ideation with structured plan (HDRS-17 item 3 score >2) or as determined by the evaluating psychiatrist
- •Depressive symptoms better explained by another psychiatric condition, a medical condition, substance use, or use of medications
- •Medical and Neurological Exclusions:
- •Any neurological disorder including but not limited to:
- •(i) History of seizure disorder or epilepsy (ii) Family history of epilepsy (first-degree relatives) (iii) Significant head trauma with loss of consciousness >5 minutes (iv) Stroke or transient ischemic attack (v) Neurodegenerative disorders (e.g., Parkinson's disease, multiple sclerosis, dementia) (vi) Brain tumor or intracranial mass lesion
- •Unstable medical condition, defined as any condition requiring acute medical intervention or hospitalization within the past 3 months, or any condition that in the investigator's judgment could affect participant safety or study outcomes
- •Contraindications to TMS/MRI:
- •Presence of ferromagnetic material in or near the head, including:
- •(i) Intracranial implants (e.g., aneurysm clips, shunts, stimulators) (ii) Cochlear implants or hearing aids (iii) Metallic facial tattoos or permanent makeup (iv) Other implanted medical devices deemed unsafe for MRI/TMS
- •Inability to tolerate MRI scanning due to claustrophobia or other reasons
- •Medication Exclusions:
- •Current use of medications known to significantly alter cortical excitability:
- •Anticonvulsants (including those used for mood stabilization)
- •Psychostimulants
- •Benzodiazepines exceeding 10mg diazepam-equivalent daily dose
- •Prior Treatment Exclusions:
- •Electroconvulsive therapy (ECT) (≥ 6 sessions) in the current depressive episode
- •Ketamine or esketamine treatment (≥ 6 sessions) in the current depressive episode
- •Use of rTMS/iTBS (≥ 15 sessions) during the current depressive episode
- •Vagus nerve stimulation (VNS) or deep brain stimulation (DBS) implantation
- •Psychotherapy:
- •Concurrent evidence-based psychotherapy is permitted if initiated >4 weeks prior to enrollment and maintained at stable frequency throughout the tria
- •Other reasons:
- •Unable to adhere to the study visit schedule
- •Planning to relocate outside the study catchment area during the trial period
- •No reliable transportation to attend study visits
- •Current participation in another research study
- •Current pregnancy (confirmed by in interview and clinical evaluation and, if deemed necessary, urine pregnancy test at screening)
- •Currently breastfeeding
结局指标
主要结局
HDRS-17 - Depression severity assessment
时间窗: From Baseline visit until week 5 visit
depression severity as assessed by the Hamilton Depression Rating Scale-17 items (HDRS-17)
次要结局
- Montgomery-Åsberg Depression Rating Scale (MADRS)(From Baseline visit until week 5 visit.)
- Quick Inventory of Depressive Symptoms-Self Report (QIDS-SR)(From Baseline visit until week 5 visit)
研究者
Andre Russowsky Brunoni
Professor and Chief of the Division of Interventional Psychiatry
University of Texas Southwestern Medical Center
研究点 (3)
Loading locations...
相似试验
尚未招募
不适用
The Impact of Neuronavigation in rTMS for Hemiplegic Stroke Patients.StrokeNCT07284017Taichung Veterans General Hospital30
招募中
不适用
Repetitive Transcranial Magnetic Stimulation in Frontotemporal Lobar DegenerationPSPFTDNCT07316413Università degli Studi di Brescia120
已完成
不适用
Dual-Task Improvement in Parkinson's Via rTMSNCT07310238University of Gaziantep41
招募中
不适用
Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's DiseaseNCT07324161Fujian Medical University Union Hospital81
招募中
2 期
Accelerated dTMS Smoking CessationNCT07292883Waypoint Centre for Mental Health Care40